2. Chemistry Strategies to Reduce Attrition in Drug Discovery
3. Emerging Drugs
Session Chair Prof. Hans Ulrich STILZ (SANOFI-AVENTIS, Malov, Denmark)
Integration of Fragment Derived Structure-Based Design into the Discovery and Development of Selective Kinase Inhibitors for Treatment of Human Cancers
Dr. Gavin HIRST (SGX PHARMACEUTICALS, San Diego, United States)
Fragment Based Lead Discovery
Prof. Roderick E. HUBBARD (UNIVERSITY OF YORK / VERNALIS, York, United Kingdom)
Search for Taxoid Mimics Using Dynamic Combinatorial Chemistry Targeting Tubulin
Ms Claire LE MANACH (ICMMO, Orsay, France)
Session Chair Dr Geoffrey STEMP (GLAXOSMITHKLINE, Harlow, United Kingdom)
From Fragment to Clinic
Dr David REES (ASTEX THERAPEUTICS, Cambridge, United Kingdom)
Chemical Strategies for Successful Clinical Development
Dr. Christopher N. JOHNSON (GLAXOSMITHKLINE, Harlow, United Kingdom)
Recent Strategies Around Predicting Oral Absorption
Dr DAVID MILLAN (PFIZER, Sandwich, United Kingdom)
Session Chair Dr Bernd RIEDL (BAYER PHARMA, Wuppertal, Germany)
The Discovery and Development of Rivaroxaban
Dr. Susanne ROEHRIG (BAYER SCHERING PHARMA, Wuppertal, Germany)
Identification and development of PI3K inhibitors - Path to the clinic
Dr. Carlos GARCIA-ECHEVERRIA (NOVARTIS PHARMA, Basel, Switzerland)
Discovery of TMC278: a Next Generation NNRTI Drug, Highly Active against Human Immunodeficiency Virus Type-1
Dr Jérôme GUILLEMONT (JANSSEN-CILAG, Val de Reuil, France)
4. Kinase Selectivity-Is it Necessary? (ACS)
5. Predictive ADME/Tox Methods: What to Apply When?
6. Macromolecular and Polymeric Drugs
Session Chair Prof. David ROTELLA (WYETH, MONTCLAIR, United States)
Kinase Selectivity in Drug Discovery - the Challenges and Opportunities
Dr. Dennis POWELL (WYETH RESEARCH, Pearl River, United States)
Development of Dibenzosuberones as Potent and Highly Selective p38 MAPK Inhibitors
Prof. Stefan LAUFER (UNIVERSITY TÜBINGEN, Tübingen, Germany)
CDK Inhibition - Selectivity Issues in Principle and in Practice
Dr. Andrew THOMAS (ASTRAZENECA R&D, Macclesfield, United Kingdom)
Session Chair Dr Scott BOYER (ASTRAZENECA, Södertälje, Sweden)
Predictive ADME: Examples from the Real World
Dr. Andrew Mark DAVIS (ASTRAZENECA R&D, Loughborough, United Kingdom)
Virtual Methods for Predicting Off-Target Pharmacology
Prof. Jordi MESTRES (IMIM AND UNIVERSITY POMPEU FABRA, Barcelona, Spain)
Predicting Brain to Blood Drug Partitioning: Progress and Limitations
Prof. Gabriele CRUCIANI (UNIVERSITY OF PERUGIA, Perugia, Italy)
Session Chair Prof. Abraham J. DOMB (HEBREW UNIVERSITY OF JERUSALEM, Jerusalem, Israel)
PEG Conjugation in Drug Development and Discovery
Prof. Francesco M. VERONESE (UNIVERSITY OF PADOVA, Padova, Italy)
Multivalency of Polymer Therapeutics Used for the Integration of Anti-angiogenic Therapy with Chemotherapy
Dr. Ronit SATCHI-FAIRANO (TEL AVIV UNIVERSITY, Tel Aviv, Israel)
5’-Phosphate Mimics within Altritol-Modified siRNAs and Inhibition of MDR1 Expression
Dr Arthur VAN AERSCHOT (KULEUVEN, LEUVEN, Belgium)
7. Fragment-Based Drug Discovery (ACS)
8. Imaging Ligands and Biomarkers (EUFEPS)
9. Natural Products as Starting Points in Drug Discovery
Session Chair Dr. Jeffrey ALBERT (ASTRAZENECA, Wilmington, United States)
EVOlution: Design and Implementation of a Fragment Discovery Platform
Dr. John BARKER (EVOTEC, OXON, United Kingdom)
Fragment-Based Discovery: What Has it Achieved so far?
Dr. Alexander ALEX (PFIZER, Sandwich, United Kingdom)
Fragment-Based Methods and the Discovery of BACE-1 Inhibitors for Alzheimer's
Dr. Jeffrey ALBERT (ASTRAZENECA, Wilmington, United States)
Session Chair Prof. Pia VUORELA (ÅBO AKADEMI UNIVERSITY, Turku, Finland)
Fluorometry and FRET in Measuring Biomarkers and Monitoring Cell Signaling Cascade
Dr. Ilkka HEMMILA (PERKINELMER LIFE SCIENCES, Turku, Finland)
Mass Sensitive Ligands Useful for Biomarker Discovery and Validation
Dr. Rainer VOEGELI (PROTEOME SCIENCES, Cobham, United Kingdom)
Design of Spin-Labeled Sulfonamides as Carbonic Anhydrase Inhibitors
Dr Alessandro CECCHI (UNIVERSITY OF FLORENCE, Sesto Fiorentino, Italy)
Session Chair Dr. Erden BANOGLU (GAZI UNIVERSITY, Ankara, Turkey)
Biodiverse Natural Products in Drug Discovery
Prof. Douglas KINGHORN (OHIO STATE UNIVERSITY, Columbus, United States)
How to Use The Structural Diversity of Natural Products for Drug Discovery
Dr. Philipp KRASTEL (NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)
Selectivity in the Antibacterial Activity of Minor Groove Binders, Derivatives of the Natural Product, Distamycin
Prof Colin SUCKLING (UNIVERSITY OF STRATHCLYDE, Glasgow, Scotland, United Kingdom)
Session Chair Dr Erin DIMAURO (AMGEN, Cambridge, United States)
Emerging Treatments for Chronic Pain: Prospects and Challenges.
Dr. Stefan MCDONOUGH (AMGEN, Cambridge, United States)
Discovery of a Selective TRPV1 Antagonist, AMG 517: A Clinical Candidate for the Treatment of Pain
Mr Mark NORMAN (AMGEN, Thousand Oaks, United States)
Novel alpha2delta Ligands for the Treatment of Neuropathic Pain
Dr. Graham N. MAW (PFIZER, Sandwich, United Kingdom)
19. Exploring the Chemical Space
20. Chemokines
21. Systems Level Research Informs Drug Target Identification and Therapy Design
Session Chair Profs. Herbert WALDMANN & STEFAN WETZEL (MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY, Dortmund, Germany)
Computer-Assisted Molecular Design: Voyages to the (un)known
Prof. Gisbert SCHNEIDER (JOHANN WOLFGANG GOETHE UNIVERSITY, Zürich, Switzerland)
The Quest for Bioisosterism in the “Other Side” of Chemical Space
Dr. Antonio MACCHIARULO (UNIVERSITY OF PERUGIA, Perugia, Italy)
Exploration of Chemical Space for Drug Discovery by Database Generation
Prof. Jean-Louis REYMOND (UNIVERSITY OF BERN, Bern, Switzerland)
Scaffold Hunter: Charting and Exploring Chemical Space
Dr. Stefan WETZEL (MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY, Dortmund, Germany)
Session Chair Prof. Gerhard ECKER (UNIVERSITY OF VIENNA, Vienna, Austria)
CXCR4 Antagonists: Relevance to Cancer Chemotherapy
Prof. Nobutaka FUJII (KYOTO UNIVERSITY, Kyoto, Japan)
Selective Dual CCR2/5 Antagonists
Dr. Wolfgang MILTZ (NOVARTIS PHARMA, Basel, Switzerland)
Biological Profiling of Anti-HIV Agents using in Silico Techniques: Insights into CCR5 Ligands Binding Through Homology Buildings, 3D-QSAR, Docking and Shape Matching Virtual Screening
Mr Antonio CARRIERI (DDIPARTIMENTO FARMACO-CHIMICO, Bari, Italy)
Session Chair Prof. Harel WEINSTEIN (CORNELL UNIVERSITY, New York, United States)
Drug Discovery, Drug Delivery and Therapeutic Monitoring by Molecular, Cellular and Functional Imaging of Atherothrombosis
Dr. Zahi A. FAYAD (MOUNT SINAI SCHOOL OF MEDICINE, New York, United States)
Understanding Drug Mechanisms and Designing Therapy at the Systems Level of the Functional Human Interactome
Prof. Gianni CESARENI (UNIVERSITY OF ROME 'TOR VERGATA', Rome, Italy)
Special Structural, Dynamic and Functional Characteristics of Membrane Proteins and their Signaling Partners that Determine the Mode and Putative Success of Therapy Design Targeting Cellular Signaling Systems.
Prof. Harel WEINSTEIN (CORNELL UNIVERSITY, New York, United States)
22. New Computational Approaches Supporting Drug Design
23. Druggability of Protein-Protein Interactions
24. Systems Biology and Medicinal Chemistry
Session Chair Prof. Jordi MESTRES (IMIM AND UNIVERSITY POMPEU FABRA, Barcelona, Spain)
Overview on New Computational Tools Supporting Drug Design
Prof. Tudor I. OPREA (UNIVERSITY OF NEW MEXICO, Albuquerque, United States)
Novel Tools for Data Gathering
Dr. Muthukumarasamy KARTHIKEYAN (NATIONAL CHEMICAL LABORATORY, Pune, India)
Novel Tools for Data Classification
Dr. Ansgar SCHUFFENHAUER (NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)
Novel Tools for Data Exploitation
Dr. Elisabet GREGORI-PUIGJANE (CHEMOTARGETS, Barcelona, Spain)
Session Chair Mr Peter NUSSBAUMER (LEAD DISCOVERY CENTER, DORTMUND, Germany)
Mapping the Binding Cite of Substrate Targeting Gamma-secretase Modulators. Phase III Candidates for Alzheimer´s Disease Utilize a Novel Protein-protein Interaction
Prof. Boris SCHMIDT (TU DARMSTADT, Darmstadt, Germany)
Rational Design of Cytotoxic Peptides from the Analysis of Protein-Protein Interactions in Microtubules
Dr pieraccini STEFANO (UNIVERSITY OF MILANO, Milano, Italy)
Peptidomimetic Inhibitors of the PSD-95/NMDA Receptor Interaction
Mr Anders BACH (UNIVERSITY OF COPENHAGEN, Copenhagen, Denmark)
Dynamic Ligation Screening: A Method for the Site-Directed Discovery of Inhibitory Fragments
